| I-03 Sulav Duwal Top-down and Bottom-Up modelling approaches in Systems Pharmacology: Understanding clinical efficacy of NRTIs against HIV-1 Wednesday 10:20-11:40 |
| I-04 Lisa Ehmann Pharmacokinetics of meropenem in critically ill patients with varying renal function Wednesday 10:20-11:40 |
| I-10 Natalie Filmann Comparing the individual and the population approach in fitting heterogeneous PK/PD data of patients with chronic hepatitis B after liver transplantation Wednesday 10:20-11:40 |
| I-19 Andy Gewitz PK/PD Modeling of Tuberculosis for Identification of Biomarkers Associated with Treatment Duration Wednesday 10:20-11:40 |
| I-41 Christoph Hethey Impact of the intracellular ribosomal concentration on in vitro bacterial growth kinetics and the antibacterial effect of linezolid on S. aureus in time-kill assays Wednesday 10:20-11:40 |
| I-43 Eef Hoeben Viral Kinetic Modeling of HCV RNA Decline during Treatment with Simeprevir in Combination with Sofosbuvir Wednesday 10:20-11:40 |
| I-52 Swati Jaiswal Pharmacokinetic-Pharmacodynamic modeling of miltefosine in Leishmania donovani infected Golden Syrian Hamsters Wednesday 10:20-11:40 |
| I-62 Anke Kip Population pharmacokinetics of plasma and intracellular miltefosine concentrations in cutaneous leishmaniasis patients Wednesday 10:20-11:40 |
| I-70 Laure Lalande Mathematical modeling and systems pharmacology of tuberculosis therapy with isoniazid Wednesday 10:20-11:40 |
| II-06 Ali Mohamed Ali Population pharmacokinetics of the amodiaquine: pooling data across different studies to optimize dosing in neglected populations Wednesday 15:10-16:30 |
| II-11 Manel Aouri Population pharmacokinetics analysis of dolutegravir in HIV-1 infected individuals Wednesday 15:10-16:30 |
| II-16 Catalina Barceló Population pharmacokinetics analysis of elvitegravir and cobicistat in HIV-1 infected individuals Wednesday 15:10-16:30 |
| II-18 Ana Bastos Using modeling and simulation to design and evaluate dosing strategies for temocillin in haemodialysis patients Wednesday 15:10-16:30 |
| II-24 Dimitra Bon PK-PD-VK modeling for hepatitis C treatment with the CI and Generalized multiscale model. Wednesday 15:10-16:30 |
| II-30 Margreke Brill Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis Wednesday 15:10-16:30 |
| II-34 Charles Burdet Joint modeling of plasma and fecal moxifloxacin pharmacokinetics in healthy volunteers Wednesday 15:10-16:30 |
| II-44 Chunli Chen Assessment of Pharmacodynamic Interactions in the Mycobacteria Tuberculosis Infected Mouse using The Multistate Tuberculosis Pharmacometric Model and the General Pharmacodynamic Interaction Model Wednesday 15:10-16:30 |
| II-50 Oskar Clewe Pre-clinical Susceptibility Characterization and Pharmacodynamic Interaction Assessment Using the Multistate Tuberculosis Pharmacometric Model Wednesday 15:10-16:30 |
| II-66 Amelia Deitchman Tetracycline against Pseudomonas aeruginosa: Pharmacokinetic/Pharmacodynamic Modeling of In Vitro Time-Kill Curves Wednesday 15:10-16:30 |
| II-69 Paolo Denti Population Pharmacokinetics of Levofloxacin in South African children. Wednesday 15:10-16:30 |
| II-72 Thomas Dorlo Translational PKPD modeling framework to assess the predictive performance of a preclinical visceral leishmaniasis hamster model Wednesday 15:10-16:30 |
| III-05 Jesmin Lohy Das Population pharmacokinetic and pharmacodynamic (PK/PD) modelling of emerging artemisinin resistance in Southern Myanmar Thursday 10:05-11:30 |
| III-10 Vincent Madelain Favipiravir pharmacokinetics in non-human primates: insights for future efficacy studies against hemorrhagic fever viruses Thursday 10:05-11:30 |
| III-15 Ben Margetts Modelling Severe Human Cytomegalovirus Infections in an Immunocompromised Paediatric Patient Population Thursday 10:05-11:30 |
| III-17 Lisa Martial Population PK model and pharmacokinetic target attainment of micafungin in ICU patients Thursday 10:05-11:30 |
| III-38 Per Olsson Gisleskog Predicting the effects of combining broadly neutralizing antibodies (bNabs) binding to different HIV viral epitopes Thursday 10:05-11:30 |
| III-49 Carlos Perez-Ruixo Population pharmacokinetics and antiviral efficacy in neonatal lambs: evidence of rapid maturation and auto-induction drug effect in metabolic clearance Thursday 10:05-11:30 |
| III-54 Kimba Eddy Phongi Population Pharmacokinetics of the Novel Antimalarial OZ439 Thursday 10:05-11:30 |
| III-62 Rachel Rose Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis. Thursday 10:05-11:30 |
| III-67 Sophie Rhodes Previous BCG vaccination associated with variation in Mycobacterial-specific immune response: a modelling study Thursday 10:05-11:30 |
| III-70 Clémence Rigaux Parasitemia clearance modeling following Ferroquine administration in P. Falciparum infected patients Thursday 10:05-11:30 |
| IV-13 Amaia Soraluce Population pharmacokinetics of linezolid in critically ill patients and treatment probability of target attainment Thursday 14:40-16:00 |
| IV-17 M. Elena Suarez Gonzalez How delayed or missed doses influence efficacy of amoxicillin in outpatients with community-acquired pneumonia: A pharmacokinetic/pharmacodynamic simulation analysis Thursday 14:40-16:00 |
| IV-19 Robin Svensson Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin Thursday 14:40-16:00 |
| IV-28 Anders Thorsted Toxicokinetics of Endotoxin and its Induction of Pro-Inflammatory Cytokines Tumor Necrosis Factor a and Interleukin-6 Thursday 14:40-16:00 |
| IV-32 Bruna Gaelzer Silva Torres Population Pharmacokinetic Modeling of Ciprofloxacin Free Lung Concentrations in Healthy and Pseudomonas aeruginosa Biofilm Infected Wistar Rats Thursday 14:40-16:00 |
| IV-40 Muhammad Usman Population Pharmacokinetics of Meropenem in Elderly Patients: Dosing simulations based on Renal Function Thursday 14:40-16:00 |
| IV-50 Max von Kleist Systems pharmacology pipeline to assess NRTI-efficacy for repurposing as pre-exposure prophylactic compounds against HIV-1 infection Thursday 14:40-16:00 |
| IV-61 Rixt Wijma Population pharmacokinetics of meropenem during intermittent and continuous infusion in healthy volunteers Thursday 14:40-16:00 |
| IV-75 Chenguang Zhou Semi-mechanistic multiple-analyte pharmacokinetic model for a THIOMAB antibiotic conjugate against Staphylococcus aureus in mouse, rat and monkey Thursday 14:40-16:00 |
